

해외 바이오의약품 임상 현황 ('22년 11월 3주)

한국바이오의약품협회, 2022.11.22.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

NCT number를 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2022.11.14. ~ 2022.11.20.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 12건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05618925	Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma	Drug: N803 Biological: CD19t-haNK suspension Drug: Cyclophosphamide Drug:	ImmunityBio, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05618925
NCT05589844	A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Procedure: Biospecimen Collection Biological: CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05589844
NCT05465954	Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma	Procedure: Biospecimen Collection Biological: Efineptakin alfa Biological: Pembrolizumab	Mayo Clinic National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05465954
NCT05361720	Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study	Drug: Cabozantinib Biological: Ipilimumab Biological: Nivolumab	Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05361720
NCT05359211	NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma	Drug: Cyclophosphamide Drug: Fludarabine Biological: Lisocabtagene Maraleucel Drug: Polymer-conjugated IL-15 Receptor Agonist NKTR-255	Fred Hutchinson Cancer Center Nektar Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05359211
NCT05345002	All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma	Drug: Retifanlimab Drug: All-trans retinoic acid	Stephen Bagley, MD, MSCE Incyte Corporation University of	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05345002
NCT05359692	INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Biological: INCAGN01876 Biological: retifanlimab	Incyte Biosciences International Sàrl Incyte Corporation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05359692
NCT05287113	Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Drug: Retifanlimab Drug: INCAGN02385 Drug: INCAGN02390 Drug: Placebo	Incyte Biosciences International Sàrl Incyte Corporation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05287113
NCT05096481	PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma	Biological: PEP-CMV Drug: Temozolomide Biological: Tetanus Diphtheria Vaccine	Nationwide Children's Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05096481
NCT05571592	Cannabidiol as a Treatment for Social Anxiety Disorder (R61)	Drug: Cannabidiol Drug: Placebo	NYU Langone Health Ananda Scientific National Center for Complementary and Integrative Health (NCCIH)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05571592
NCT05245292	3BNC117-LS and 10-1074-LS Plus N-803 (bNab+N-803)	Drug: 3BNC117-LS Drug: 10-1074-LS Drug: N803	Rockefeller University National Institute of Allergy and Infectious Diseases (NIAID) Weill Medical College of Cornell University Perelman School of Medicine University of Pennsylvania	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05245292
NCT05577182	Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies	Drug: INCA32459-101	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05577182

해외 바이오의약품 임상 현황 ('22년 11월 3주)

한국바이오의약품협회, 2022.11.22.

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05429268	Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)	Drug: Tafasitamab Drug: Lenalidomide	Incyte Corporation	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05429268

○ 프랑스 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05287113	Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS≥1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Drug: Retifanlimab Drug: INCAGN02385 Drug: INCAGN02390 Drug: Placebo	Incyte Biosciences International Sàrl Incyte Corporation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05287113

○ 독일 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05287113	Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS≥1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Drug: Retifanlimab Drug: INCAGN02385 Drug: INCAGN02390 Drug: Placebo	Incyte Biosciences International Sàrl Incyte Corporation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05287113

○ 중국 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT04465734	A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC	Drug: HLX10 Drug: HLX04 Drug: Sorafenib	Shanghai Henlius Biotech	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT04465734
NCT05607498	First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors	Drug: EMB07	EpimAb Biotherapeutics (Suzhou)Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05607498
NCT05552976	A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)	Drug: CC-92480 Drug: Carfilzomib Drug: Dexamethasone	Bristol-Myers Squibb	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05552976

○ 일본 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05623020	A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant	Drug: Elranatamab Drug: Daratumumab Drug: Lenalidomide Drug: Dexamethasone	Pfizer	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05623020